Kendall C Browne1, Malki Stohl1, Kipling M Bohnert1, Andrew J Saxon1, David S Fink1, Mark Olfson1, Magdalena Cerda1, Scott Sherman1, Jaimie L Gradus1, Silvia S Martins1, Deborah S Hasin1. 1. Center of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, Philadelphia (Browne, Saxon); Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Healthcare System, Seattle (Browne); Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Browne, Saxon); New York State Psychiatric Institute, New York (Stohl, Fink, Olfson, Hasin); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, and VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor (Bohnert); Department of Epidemiology, Columbia University Mailman School of Public Health, New York (Fink, Olfson, Martins, Hasin); Department of Psychiatry, Columbia University Medical Center, New York (Olfson, Hasin); Department of Population Health, New York University, New York (Cerda, Sherman); Department of Epidemiology, Boston University, Boston (Gradus).
Abstract
OBJECTIVE: The authors sought to estimate the prevalence of past-12-month and lifetime cannabis use and cannabis use disorder among U.S. veterans; to describe demographic, substance use disorder, and psychiatric disorder correlates of nonmedical cannabis use and cannabis use disorder; and to explore differences in cannabis use and cannabis use disorder prevalence among veterans in states with and without medical marijuana laws. METHODS: Participants were 3,119 respondents in the 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III) who identified as U.S. veterans. Weighted prevalences were calculated. Logistic regression analyses tested associations of nonmedical cannabis use and cannabis use disorder with demographic and clinical correlates and examined whether prevalence differed by state legalization status. RESULTS: The prevalences of any past-12-month cannabis use and cannabis use disorder were 7.3% and 1.8%, respectively. Lifetime prevalences were 32.5% and 5.7%, respectively. Past-12-month and lifetime cannabis use disorder prevalence estimates among nonmedical cannabis users were 24.4% and 17.4%, respectively. Sociodemographic correlates of nonmedical cannabis use and use disorder included younger age, male gender, being unmarried, lower income, and residing in a state with medical marijuana laws. Nonmedical cannabis use and use disorder were associated with most psychiatric and substance use disorders examined. CONCLUSIONS: Among veterans, the odds of nonmedical cannabis use and use disorder were elevated among vulnerable subgroups, including those with lower income or psychiatric disorders and among survey participants residing in states with medical marijuana laws. The study findings highlight the need for clinical attention (e.g., screening, assessment) and ongoing monitoring among veterans in the context of increasing legalization of cannabis.
OBJECTIVE: The authors sought to estimate the prevalence of past-12-month and lifetime cannabis use and cannabis use disorder among U.S. veterans; to describe demographic, substance use disorder, and psychiatric disorder correlates of nonmedical cannabis use and cannabis use disorder; and to explore differences in cannabis use and cannabis use disorder prevalence among veterans in states with and without medical marijuana laws. METHODS: Participants were 3,119 respondents in the 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III) who identified as U.S. veterans. Weighted prevalences were calculated. Logistic regression analyses tested associations of nonmedical cannabis use and cannabis use disorder with demographic and clinical correlates and examined whether prevalence differed by state legalization status. RESULTS: The prevalences of any past-12-month cannabis use and cannabis use disorder were 7.3% and 1.8%, respectively. Lifetime prevalences were 32.5% and 5.7%, respectively. Past-12-month and lifetime cannabis use disorder prevalence estimates among nonmedical cannabis users were 24.4% and 17.4%, respectively. Sociodemographic correlates of nonmedical cannabis use and use disorder included younger age, male gender, being unmarried, lower income, and residing in a state with medical marijuana laws. Nonmedical cannabis use and use disorder were associated with most psychiatric and substance use disorders examined. CONCLUSIONS: Among veterans, the odds of nonmedical cannabis use and use disorder were elevated among vulnerable subgroups, including those with lower income or psychiatric disorders and among survey participants residing in states with medical marijuana laws. The study findings highlight the need for clinical attention (e.g., screening, assessment) and ongoing monitoring among veterans in the context of increasing legalization of cannabis.
Entities:
Keywords:
Cannabis; Cannabis Use Disorder; NESARC-III; Substance-Related and Addictive Disorders; Veterans
Authors: Ranak B Trivedi; Edward P Post; Haili Sun; Andrew Pomerantz; Andrew J Saxon; John D Piette; Charles Maynard; Bruce Arnow; Idamay Curtis; Stephan D Fihn; Karin Nelson Journal: Am J Public Health Date: 2015-10-16 Impact factor: 9.308
Authors: Aaron L Sarvet; Melanie M Wall; Katherine M Keyes; Mark Olfson; Magdalena Cerdá; Deborah S Hasin Journal: Drug Alcohol Depend Date: 2018-03-02 Impact factor: 4.492
Authors: Marina Goldman; Jesse J Suh; Kevin G Lynch; Regina Szucs; Jennifer Ross; Hu Xie; Charles P O'Brien; David W Oslin Journal: J Addict Med Date: 2010-03 Impact factor: 3.702
Authors: Paris Charilaou; Kanishk Agnihotri; Pablo Garcia; Apurva Badheka; Douglas Frenia; Balaji Yegneswaran Journal: Am J Med Date: 2017-02-02 Impact factor: 4.965
Authors: Deborah S Hasin; Bradley T Kerridge; Tulshi D Saha; Boji Huang; Roger Pickering; Sharon M Smith; Jeesun Jung; Haitao Zhang; Bridget F Grant Journal: Am J Psychiatry Date: 2016-03-04 Impact factor: 18.112
Authors: Deborah S Hasin; Dvora Shmulewitz; Magdalena Cerdá; Katherine M Keyes; Mark Olfson; Aaron L Sarvet; Melanie M Wall Journal: Am J Psychiatry Date: 2020-01-22 Impact factor: 18.112
Authors: Robert H Pietrzak; Adrienne J Heinz; Brienna N Meffert; Danielle M Morabito; Danielle A Sawicki; Catherine Hausman; Steven M Southwick Journal: Prim Care Companion CNS Disord Date: 2019-01-17